BrainStorm’s data appear beyond limits of FDA flexibility in ALS

Even with new biomarker data and efficacy analyses, FDA is still not buying BrainStorm’s argument for efficacy of ALS therapy NurOwn.

In briefing materials released ahead of Wednesday's advisory committee meeting, FDA criticized the company’s post hoc subgroup analyses and emphasized a concerning survival signal...